GLP-1 Drugs Explained: Class, Mechanism, and Genetics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub, your resource for evidence-based guidance on GLP-1 therapies and the genetic variables behind every metabolic decision. The GLP-1 drug class has moved from a niche diabetes tool to one of the most discussed categories in medicine. Understanding it starts with the hormone the drugs are named after, then extends to how the receptor agonist class works, which compounds are FDA-approved, and the genetic terrain underneath.

What GLP-1 actually is

Native GLP-1 is a 30- to 31-amino-acid peptide secreted by intestinal L-cells. After release, it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and engages central satiety circuits in the hypothalamus. Native GLP-1 has a very short half-life of about 2 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4, known as DPP-4.

How GLP-1 receptor agonist drugs work

GLP-1 receptor agonist medications are engineered to resist DPP-4 degradation, extending half-life from minutes to days or weeks. They bind the same GLP-1 receptor as the native hormone, driving the same downstream effects on insulin secretion, glucagon suppression, gastric emptying, and satiety.

The dual-agonist distinction

Tirzepatide-based compounds add agonism at the GIP receptor, a related incretin receptor. That second mechanism is one of the key molecular distinctions in the class as of April 2026, and it is why the terms GLP-1 agonist and GIP/GLP-1 dual agonist describe different tools within the same broad family.

FDA-approved GLP-1 medications as of April 2026

The FDA-approved GLP-1 receptor agonist class includes exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to obstructive sleep apnea, 2024). Investigational compounds in late-stage development include retatrutide, a GIP/GLP-1/glucagon triple agonist, and orforglipron, an oral non-peptide small-molecule GLP-1 receptor agonist. Investigational compounds are not FDA-approved and are not sold by PlexusDx.

Why genetic context matters in the GLP-1 pathway

GLP-1 receptor agonists work by engaging a receptor pathway that carries natural genetic variation. the GLP-1 receptor gene itself, is the most direct upstream variable; its variants influence receptor density and downstream incretin signaling efficiency. FTO, the fat-mass and obesity-associated gene, carries common variants that influence appetite regulation and adiposity set-point. MC4R, the melanocortin-4 receptor gene, has variants that influence satiety signaling and total energy intake. TCF7L2 variants influence insulin secretion and incretin response. These are pathway-level variables; they describe the metabolic terrain any compound must work on rather than predicting response to one drug.

The PlexusDx approach

PlexusDx offers GLP-1 receptor agonists through its Weight Management Protocols. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology. It does not recommend, prescribe, or predict response to any specific peptide and is not a pharmacogenomic test; it adds upstream context for an informed provider conversation.

Brand, molecule, and indication are not the same thing

One source of confusion in the GLP-1 category is that a single molecule can appear under multiple brand names with different approved uses. Semaglutide, for example, is marketed as more than one product, and the brand a prescription names is tied to a specific FDA-approved indication. That distinction matters for coverage, because the same molecule under a different brand is not automatically interchangeable for insurance purposes.

Why the pathway framing is useful

Thinking in terms of the pathway rather than a single brand helps make sense of a fast-moving field. New compounds continue to enter development, some adding mechanisms like GIP or glucagon agonism, but they share the same core GLP-1 biology. Understanding that shared foundation gives you a durable framework for evaluating whatever product a provider discusses with you.

How the class evolved over time

The GLP-1 class did not appear all at once. It grew from earlier compounds with short dosing intervals toward molecules engineered for longer action and, more recently, toward dual and triple mechanisms and oral formulations. Each step reflected the same goal: extending and refining the natural GLP-1 signal while improving convenience and effect. Reading the approval timeline, from the earliest injectable options to the newest dual agonists and investigational triple agonists, gives a sense of how quickly the field has moved and why staying oriented to the underlying pathway is more durable than tracking any single product.

Frequently Asked Questions

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone secreted by intestinal L-cells in response to food intake. GLP-1 stimulates glucose-dependent insulin release, slows gastric emptying, and signals satiety to the brain. The GLP-1 receptor agonist drug class mimics these effects pharmacologically.

Are GLP-1 medications and GLP-1 inhibitors the same thing?

No, they are opposites. GLP-1 receptor agonists activate the GLP-1 receptor and produce the hormone's effects. There is no widely used class called GLP-1 inhibitors in current clinical practice. DPP-4 inhibitors are different; they reduce breakdown of native GLP-1 but do not activate the receptor directly.

How are GLP-1 receptor agonists administered?

Most FDA-approved GLP-1 receptor agonists are given as subcutaneous injections, weekly or daily depending on the compound. Rybelsus is the only FDA-approved oral option as of April 2026. Compounded oral GLP-1 protocols exist through licensed compounding pharmacy pathways and are not FDA-approved as branded products.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.